Syntex
Executive Summary
Firm announces agreement to market ten monoclonal antibody-based in vitro tests from Atlanta-based Murex, including tests for pregnancy, ovulation, chlamydia, and strep A. In addition, Syntex reports that it holds an equity position in Murex -- the sixth such investment since the company began its biotechnology venture program.